Cvrx, Inc. ( (CVRX) ) has realeased its Q3 earnings. Here is a breakdown of the information Cvrx, Inc. presented to its investors.
CVRx, Inc. is a commercial-stage medical device company that specializes in neuromodulation solutions for cardiovascular diseases, with its flagship product Barostim designed to improve heart failure symptoms. The company has reported a strong performance in the third quarter of 2024 with significant revenue growth driven by the adoption of its Barostim therapy. Total revenue for the quarter reached $13.4 million, marking a 27% increase compared to the same period last year.
A notable highlight from CVRx’s report is the 30% revenue growth in the U.S. heart failure segment, underscoring the expanding presence of Barostim in the market. With 208 active implanting centers in the U.S., a 31% increase from the previous year, the company is well-positioned to capitalize on growing demand. Additionally, the reassignment of Barostim to a higher-paying Medicare category and the approval of new procedural codes by the American Medical Association are expected to boost future earnings.
Despite the positive revenue trajectory, CVRx reported a net loss of $13.1 million for the quarter, an increase from the previous year’s $9.0 million. The loss is attributed to higher operating expenses, particularly in selling, general, and administrative costs, which rose by 38% due to increased compensation and advertising. The company’s gross profit improved by 26% to $11.1 million, maintaining a strong gross margin of 83%.
Looking ahead, CVRx remains optimistic about its growth prospects. The company expects its full-year 2024 revenue to be in the range of $50.5 million to $51.5 million, driven by the continued adoption of Barostim. As they focus on enhancing patient access, education, and awareness, CVRx is poised to strengthen its market position in the cardiovascular sector.
